Actively Recruiting
Phase 1 Study of ACL Reconstruction Using Patients Own Fat Pad Derived Stem Cells Single Injection of Autologous Mesenchymal Stromal Cells to Improve Knee Healing
Led by The Methodist Hospital Research Institute · Updated on 2026-04-16
15
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a single injection of mesenchymal stromal cells taken from a patients own infrapatellar fat pad during anterior cruciate ligament ACL reconstruction surgery. This pilot clinical study is designed as a prospective, open-label, single-arm trial focusing on patients undergoing ACL reconstruction with a patellar tendon autograft. The study seeks to understand how these cells may impact recovery following surgery. Each participant will receive one intra-articular injection of autologous mesenchymal stromal cells about 21 days after their ACL reconstruction surgery. These cells are collected during the surgery, cultured, modified, and prepared to contain 50 million cells in a 1.5 ml dose. This treatment is administered in a single clinic visit following the surgical procedure. Participants will be monitored through several follow-up visits up to 6 months after surgery. Assessments include tracking treatment-related adverse events, knee function, pain, swelling, and time taken to return to sports activities. Evaluations occur preoperatively and at 6 weeks, 3.5 months, and 6 months postoperatively to measure the studys outcomes and monitor safety throughout the study period.
CONDITIONS
Brief Title
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
Research Team
M
Madison Bowden
H
Haley Goble
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here